Evidence map›Paper›PMID 37799378›Full record

ReviewActa pharmaceutica Sinica. B2023

Lipid carriers for mRNA delivery.

Wanting Zhang, Yuxin Jiang, Yonglong He, Hamza Boucetta, Jun Wu, Zhongjian Chen, Wei He

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wanting ZhangDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Yuxin JiangDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Yonglong HeDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Hamza BoucettaDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Jun WuDepartment of Geriatric Cardiology, Jiangsu Provincial Key Laboratory of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Zhongjian ChenShanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.
Wei HeShanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Messenger RNA (mRNA) is the template for protein biosynthesis and is emerging as an essential active molecule to combat various diseases, including viral infection and cancer. Especially, mRNA-based vaccines, as a new type of vaccine, have played a leading role in fighting against the current global pandemic of COVID-19. However, the inherent drawbacks, including large size, negative charge, and instability, hinder its use as a therapeutic agent. Lipid carriers are distinguishable and promising vehicles for mRNA delivery, owning the capacity to encapsulate and deliver negatively charged drugs to the targeted tissues and release cargoes at the desired time. Here, we first summarized the structure and properties of different lipid carriers, such as liposomes, liposome-like nanoparticles, solid lipid nanoparticles, lipid-polymer hybrid nanoparticles, nanoemulsions, exosomes and lipoprotein particles, and their applications in delivering mRNA. Then, the development of lipid-based formulations as vaccine delivery systems was discussed and highlighted. Recent advancements in the mRNA vaccine of COVID-19 were emphasized. Finally, we described our future vision and perspectives in this field.

Indexed as

COVID-19Drug deliveryEncapsulation efficiencyEndosome escapeLipid carriersmRNANanoparticlesVaccine

Identifiers

PMID37799378
PMCPMC10547918

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.